Patent · US Active

Combinations of pyrazole kinase inhibitors

US8404718B2 · kind B2 · utility

5Cited by
24References
22Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 1, 2010
Grant dateMar 26, 2013
Priority date
Expiry dateDec 20, 2030

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides a combination comprising a cytotoxic compound, a signalling inhibitor, an ancillary agent, or two or more further anti-cancer agents, and a compound having the formula (Ib):or salts or tautomers or N-oxides or solvates thereof;wherein

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.